Dyadic International, Inc. announced a leadership change as part of its ongoing strategic shift, appointing Joe Hazelton as President, effective immediately. Mr. Hazelton will also continue in his role as Chief Operating Officer, aligning leadership with the company's commercial focus.
Mark Emalfarb will continue to serve as Chief Executive Officer and a member of the Board of Directors, overseeing legacy biopharmaceutical programs, funding, and intellectual property strategy. This appointment ensures focused and prioritized execution across Dyadic’s technical, operational, and commercial efforts.
The company cited commercial validation through several high-value transactions, including a partnership with Proliant Health and Biologicals for recombinant human albumin, a collaboration with a non-animal dairy enzyme company, and a joint venture with Fermbox Bio that launched EN3ZYME, which recently received a significant purchase order.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.